

Determined to realize a future in which
people with cancer live longer and
better than ever before



Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Syndax investment highlights



Entinostat IO

Combined with anti-PD-1:

- Signals in Mel, NSCLC
- Ongoing trials in NSCLC, Mel, TNBC, Ovar, CRC
- Multiple near term readouts

Entinostat HR+ Breast Cancer

Combined with exemestane:

- Breakthrough designation
- Phase 3 ongoing

SNDX-6352

CSF1-R antibody

- Phase 1 ongoing
- Broad clinical potential

Strong management team and cash position

CRC - colorectal cancer; NSCLC - non-small cell lung cancer; Mel - melanoma; TNBC - triple negative breast cancer; Ovar - ovarian cancer

Previous milestones


ENTINOSTAT (Class 1 specific HDAC inhibitor)	outcome	2Q17	3Q17	4Q17	1H18
ENCORE 601 - NSCLC (PD-1 Naive) decision to re-open Phase 2	pending	●			
ENCORE 601 - NSCLC (PD-1 pre-Tx) decision to re-open Phase 2	✓	●			
ENCORE 601 - Complete enrollment melanoma cohort (stage 2)	✓		● ←	●	
ENCORE 601 - Present stage 1 melanoma data at ASCO	✓	●			
ENCORE 601 - FDA Type B meeting melanoma development path	✓	●			
ENCORE 602 - Complete enrollment Phase 2 TNBC study				●	
E2112 - Per ECOG, complete Phase 3 enrollment; release PFS				●	●

SNDX-6352 (anti-CSF-1R mAB)	outcome	2Q17	3Q17	4Q17	1H18
Initiate MAD trial (cancer patients)			●		
Anticipate SAD trial data presentation (healthy volunteers)				●	


To date, the two cohorts exploring the combination in PD(L)-1 pretreated patients have expanded to stage 2

Entinostat + KEYTRUDA®

Phase 2: Simon 2-stage design




Despite important advances, unmet need exists for melanoma patients



- 75-80% of Stage IV melanoma patients receive 1L PD-1 therapy[^]
- ~10,000 US patients* expected to require treatment after PD-1 antagonist

Source: [^]Kantar 2016 Treatment Architecture report; ^{*}Trial Trove, SEER data,

Other ongoing Entinostat + PD-L1 combinations: ENCORE 602 and 603




Phase 2 ENDPOINTS:

- Primary endpoint - PFS
- Secondary endpoint - Overall response rate (ORR)
- Secondary endpoint - Overall survival (OS)

E2112: Phase 3 registration trial in advanced HR+, HER2- breast cancer

Exemestane +/- entinostat




**PFS and OS
co-primary
endpoints**

- Per ECOG-ACRIN, enrollment completion and PFS data release possible 1H18
- Potential NDA filing 2018 based upon positive PFS data
- **GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION**

Entinostat: Blockbuster potential as 2nd/3rd line therapy for HR+, HER2- metastatic breast cancer


First novel MOA in HR+ BC with Phase 3 data since CDK4/6

Leading treatment options - HR+, HER2- advanced breast cancer



Source: DataMonitor 2016 Breast cancer: HR+/HER2- Disease Coverage Report

SNDX-6352: Anti-CSF-1R Ab targeting TAMs to increase tumor infiltrating lymphocytes



- High affinity, IgG4 ($K_D = 4-8$ pM)
- Broad potential clinical utility
- ✓ Phase 1, single ascending dose (SAD) trial completed
- Multiple ascending dose (MAD) trial will initiate 3Q17
 - To enroll patients with solid tumors

TAM - tumor associated macrophage; CSF-1R - colony stimulating factor -1 receptor










Source : Ordentlich, P. et al SITC 2016

2Q17 Financial highlights and 2017 guidance

Ticker	SNDX (NASDAQ)	
As of June 30, 2017		
Cash and short-term investments	\$130.0 million	
Common shares O/S	22.2 million	
2017 Operating Expense Guidance		
	<u>Q3</u>	<u>2017</u>
R&D	\$12-14 M	\$46-51 M
Total Operating Expenses	\$16-18 M	\$63-68 M

Includes \$48.7 M in net proceeds raised through sale of 3.9 M shares

Upcoming milestones

ENTINOSTAT (Class 1 specific HDAC inhibitor)		3Q17	4Q17	1H18	2H18
	ENCORE 601 - Go / No go decision on Naïve NSCLC cohort				
➤	ENCORE 601 - Present biomarker analysis (Melanoma)				
➤	ENCORE 601 - Present stage 1 NSCLC data				
➤	ENCORE 601 - Go / No go decision on Stage 1 of CRC cohort				
➤	ENCORE 601 - Present full Phase 2 results for melanoma and pre-Tx NSCLC and stage 1 results for CRC (n=13)				
	E2112 - Per ECOG, complete Phase 3 enrollment; release PFS				
➤	ENCORE 602 - Present Phase 2 results (TNBC)				
SNDX-6352 (anti-CSF-1R mAB)		3Q17	4Q17	1H18	2H18
	SAD trial data presentation (healthy volunteers)				
➤	MAD trial data presentation (patients with solid tumors)				

➤ NEW Milestone

Syndax investment highlights



Entinostat IO

Combined with anti-PD-1:

- Signals in Mel, NSCLC
- Ongoing trials in NSCLC, Mel, TNBC, Ovar, CRC
- Multiple near term readouts

Entinostat HR+ Breast Cancer

Combined with exemestane:

- Breakthrough designation
- Phase 3 ongoing

SNDX-6352

CSF1-R antibody

- Phase 1 ongoing
- Broad clinical potential

Strong management team and cash position

CRC - colorectal cancer; NSCLC - non-small cell lung cancer; Mel - melanoma; TNBC - triple negative breast cancer; Ovar - ovarian cancer

Thank you. Questions?

Syndax 